🗞️ Why in News The Union Budget 2026-27 allocated Rs 10,000 crore for Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation), aiming to transform India from the “Pharmacy of the World” for generics into a global biologics and biosimilars manufacturing hub.
The Editorial Argument
The Economic Times argues that Biopharma SHAKTI correctly identifies the next frontier for India’s pharmaceutical industry — but success depends on overcoming structural bottlenecks in regulatory speed, research infrastructure, and clinical trial capacity that have kept India at just 3.2% of the global biosimilars market.
The Generics-Biologics Paradox
| Parameter | Generics | Biologics |
|---|---|---|
| Molecule type | Small chemical molecules | Large complex proteins from living cells |
| Replication | Exact copy possible | Only “similar” versions (biosimilars) |
| Manufacturing | Chemical synthesis | Cell culture, fermentation — requires specialised facilities |
| Regulatory pathway | ANDA (abbreviated) | Full analytical + clinical studies needed |
| India’s global share | ~20% | ~3.2% |
| Market size (global) | ~$400 billion | ~$500 billion (growing to $800B by 2030) |
India dominates generics because the pathway is well-established: reverse-engineer the chemical formula, prove bioequivalence, manufacture at scale. Biologics are fundamentally different — they require living cell cultures, cold chain logistics, and extensive clinical validation.
What SHAKTI Proposes
| Component | Detail |
|---|---|
| NIPERs | 3 new + 7 upgraded |
| Clinical trial sites | 1,000+ accredited |
| CDSCO strengthening | Dedicated scientific review cadre |
| Non-animal testing | Shift to 3Rs (Replace, Reduce, Refine) |
| Budget | Rs 10,000 crore |
The Bottlenecks
- Regulatory speed: India’s CDSCO takes 12-18 months for biosimilar approval vs 10 months at the US FDA
- Research talent: India produces abundant pharma graduates but few with biomanufacturing expertise
- Cold chain: Biologics require -20°C to -80°C storage; India’s cold chain infrastructure is inadequate outside metros
- Clinical trial capacity: India conducts only ~3% of global clinical trials despite having 17% of the world’s population
- IP barriers: Many originator biologics are still under patent protection in key markets
Indian Biosimilar Leaders
| Company | Key Biosimilar |
|---|---|
| Biocon | Trastuzumab (breast cancer), Insulin Glargine |
| Dr Reddy’s | Rituximab (blood cancer) |
| Cipla | Adalimumab (autoimmune) |
| Zydus | Pegfilgrastim (neutropenia) |
These companies have achieved US FDA and EMA approvals for biosimilars, proving India can compete — but at a scale far below potential.
Global Context
The biologics revolution is reshaping healthcare:
- Cancer immunotherapy (checkpoint inhibitors) — $50+ billion market
- GLP-1 agonists (semaglutide for diabetes and obesity) — $40+ billion market
- Gene therapies — emerging, with treatments costing $2-3 million per patient
- mRNA vaccines — proven during COVID, now expanding to cancer and rare diseases
India’s cost advantage — manufacturing at 30-40% lower cost than Western competitors — is a massive opportunity if the regulatory and infrastructure gaps are closed.
UPSC Relevance
Prelims: NIPER Act 1998, CDSCO, DCGI, Drugs and Cosmetics Act 1940, biologics vs biosimilars, 3Rs principle
Mains GS-3: India’s pharmaceutical industry; Make in India for healthcare; S&T policy for economic growth
📌 Facts Corner — Knowledgepedia
Biopharma SHAKTI:
- Full form: Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation
- Budget: Rs 10,000 crore
- NIPERs: 3 new + 7 upgraded (total 10)
- Clinical trial sites: 1,000+
- Non-animal testing: 3Rs principle
India Pharma Industry:
- Global rank: 3rd by volume
- Generics: 20% of global supply
- Vaccines: 60% of global supply
- Biosimilar share: 3.2% globally
- Domestic biosimilars: 95+ approved
- Industry size: ~$50 billion
- Exports: ~$28 billion/year
Global Biologics Market:
- 2025: ~$500 billion
- 2030 (projected): ~$800 billion
- Growth rate: 8-10% annually
- Top companies: Roche, AbbVie, Amgen, J&J
Other Relevant Facts:
- India’s clinical trial share: ~3% of global
- CDSCO approval time: 12-18 months
- US FDA approval: ~10 months
- NIPERs: 7 currently (est. under NIPER Act 1998)
- Indian Pharmacopoeia Commission: sets drug quality standards
Sources: Economic Times, Business Standard